Mesothelin-Targeted Immunotherapy Crs-207 In Combination With Standard Of Care Chemotherapy As Treatment For Malignant Pleural Mesothelioma (Mpm).

7565 Background: MPM is an aggressive disease with poor prognosis and is relatively refractory to currently available therapies. CRS-207 is live-attenuated Listeria monocytogenes engineered to express the tumor-associated antigen mesothelin. Stimulation of potent innate and adaptive immunity by CRS-207 may act synergistically in combination with chemotherapy that alters the tumor environment to be more susceptible to immune-mediated killing. Methods: Eligible patients were chemotherapy-naive with unresectable MPM, good performance status (ECOG 0 or 1) and adequate organ function. Patients received 2 prime vaccinations with CRS-207 (1 × 109 CFU) 2 weeks apart, followed by 6 cycles of pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) 3 weeks apart and 2 CRS-207 boost vaccinations 3 weeks apart. Subjects were followed every 8 weeks until disease progression. Clinically stable patients received CRS-207 maintenance vaccinations every 8 weeks. Objectives of the study include safety, immunogenicity, objective tumo...